Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
MWN-AI** Summary
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in targeted radiotherapies, is set to present two abstracts at the 2026 American Association for Cancer Research (AACR) Annual Meeting, from April 17-22 in San Diego. The presentations will focus on their innovative assets, ATNM-400 and Actimab-A, which target solid tumors and hematologic malignancies, respectively.
Scheduled for April 21, 2026, both abstracts fall under the Experimental and Molecular Therapeutics category, showcasing Actinium’s unique biology-driven approach to radiotherapy. Key highlights include the emphasis on targeting resistance-associated biology rather than merely tumor surface expression, and the utilization of Actinium-225’s high-linear energy transfer (LET) properties to deliver potent, tumor-specific cytotoxicity.
ATNM-400, Actinium's flagship candidate, is in development for multiple cancers, including prostate, non-small cell lung, and breast cancers. It selectively targets markers associated with advanced prostate cancer, demonstrating preclinical superiority over current therapies such as enzalutamide and 177Lu-PSMA-617. This innovative approach has shown promise as a monotherapy and in combination with other treatments.
Actimab-A, the company’s advanced therapeutic for acute myeloid leukemia, has shown substantial activity in relapsed and refractory cases, leading to a pivotal Phase 2/3 trial supported by collaboration with the National Cancer Institute. This trial will explore synergies with established therapies like Venetoclax in frontline AML settings.
With a portfolio rich in potential, including its preclinical programs and a robust patent strategy, Actinium Pharmaceuticals is poised for significant advancements in oncology therapeutics, with expectations of meaningful improvements in patient outcomes. Further details on the abstracts will be publicly available on March 17, 2026.
MWN-AI** Analysis
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is poised for significant visibility and investor interest as it prepares to present two abstracts at the upcoming AACR Annual Meeting in April 2026. The company's focus on targeted radiotherapies, particularly their lead candidate ATNM-400 and Actimab-A, positions them within the rapidly evolving oncology market.
The upcoming presentations highlight key advancements in Actinium’s pipeline, with ATNM-400 showing promise across multiple cancer types, including prostate, non-small cell lung cancer (NSCLC), and breast cancer. This innovative approach, targeting resistance-associated biology, may effectively overcome treatment limitations of existing therapies like enzalutamide and osimertinib. Such data could drive positive sentiment in the market, particularly if the results reveal significant efficacy and safety profiles.
Moreover, Actimab-A's role as a backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies adds to the company’s appeal. Its collaborative development with the National Cancer Institute further validates its potential and could enhance its market penetration if successful in upcoming trials.
Investors should closely monitor the results of these abstracts, as positive reception could spur increased institutional investment and interest from analysts. However, it's essential to remain cautious, given that biotech stocks often experience volatility linked to clinical trial outcomes and regulatory approvals. The company's recent advancements in preclinical programs for solid tumors further indicate a commitment to expanding its therapeutic reach, potentially adding value.
In conclusion, while Actinium holds promising prospects, potential investors should evaluate the risk-reward profile carefully, particularly ahead of the AACR meeting, as the outcomes could significantly influence market perception and stock performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology Applications
NEW?YORK, Feb. 17, 2026 /PRNewswire/ --?Actinium Pharmaceuticals, Inc. (NYSE American:?ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, today announced that it will present two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California.
Both abstracts are scheduled for presentation in the Experimental and Molecular Therapeutics category under the session titled Radiopharmaceutical Platforms for Theranostic Precision Oncology on April 21, 2026.
In accordance with AACR embargo policies, details of the abstracts, including titles and full text, will become publicly available on March 17, 2026, at 4:30 PM ET via the AACR Online Program Planner.
Presentation Details
Presentation #1:
Session Category: Experimental and Molecular Therapeutics
Session Title: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Session Date & Time: April 21, 2026 | 2:00 PM – 5:00 PM PT
Location: Poster Section 16
Poster Board Number: 18
Poster Number: 5824
Presentation #2:
Session Category: Experimental and Molecular Therapeutics
Session Title: Radiopharmaceutical Platforms for Theranostic Precision Oncology
Session Date & Time: April 21, 2026 | 2:00 PM – 5:00 PM PT
Location: Poster Section 16
Poster Board Number: 21
Poster Number: 5827
Actinium's Platform Strategy for Long-Term Value Creation
The AACR 2026 data will highlight Actinium's differentiated biology-driven approach to targeted radiotherapy development including:
- Targeting resistance-associated biology rather than tumor surface expression alone
- Leveraging the high-linear energy transfer (LET) of Ac-225 to deliver potent, tumor-specific cytotoxicity
- Building a radiotherapy franchise comprised of multiple pan-tumor assets
Sandesh?Seth, Chairman and CEO of Actinium Pharmaceuticals, commented, "We are pleased to have two abstracts accepted for presentation at AACR 2026. Participation in this meeting provides an important opportunity to engage with the Oncology research community. We look forward to sharing additional details once the abstracts are publicly released in accordance with AACR guidelines."
About Actinium Pharmaceuticals, Inc.
Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. ATNM-400, Actinium's lead product candidate, is a novel, first-in-class, and multi-indication Actinium-225 (Ac-225) in development for prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer. The antigen specifically targeted by ATNM-400 is highly expressed in metastatic castration-resistant prostate cancer (mCRPC), contributes directly to disease progression, poorer survival outcomes, and continues to be expressed at a high level even after androgen receptor inhibitor (ARPI) and Pluvicto® treatment. ATNM-400 is supported by preclinical data demonstrating tumor-specific uptake, higher efficacy than androgen receptor inhibitor enzalutamide (Xtandi®) and 177Lu-PSMA-617 radiotherapy, the active agent in Pluvicto®, durable tumor control and potent efficacy in prostate cancer models resistant to both enzalutamide and 177Lu-PSMA-617. In addition, ATNM-400 has demonstrated synergy with enzalutamide. In NSCLC, ATNM-400 showed superior efficacy to EGFR targeting therapies including osimertinib (TARGRISSO®, AstraZeneca), Dato-DXd (DATROWAY®, AstraZeneca/Daiichi Sankyo) and amivantamab (RYBREVANT®, J&J) with synergistic activity in combination with osimertinib. In breast cancer, ATNM-400 works as monotherapy in triple-negative breast cancer, hormone-positive breast cancer and also in HER2-therapy trastuzumab (HERCEPTIN® Roche) resistant breast cancer and endocrine therapy-resistant breast cancer models. The data generated to date with ATNM-400 supports its potential across treatment settings to be used either as a monotherapy, or in combination or sequenced with other therapies. Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, that is a potential backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds approximately 240 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.
For more information, please visit: https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Investors:
investorrelations@actiniumpharma.com
SOURCE Actinium Pharmaceuticals, Inc.
FAQ**
How do the upcoming presentations at the 2026 AACR Annual Meeting showcase the unique advantages of Actinium Pharmaceuticals Inc. ATNM's Ac-225 targeted radiotherapy in comparison to conventional treatment methods in oncology?
What specific results and insights does Actinium Pharmaceuticals Inc. ATNM expect to disclose from the abstracts related to ATNM-400 and Actimab-A programs at the AACR 20that could influence investor confidence?
How is Actinium Pharmaceuticals Inc. ATNM's strategy to target resistance-associated biology expected to improve patient outcomes in prostate cancer, NSCLC, and breast cancer, as highlighted in their 2026 AACR presentations?
In what ways do the collaboration efforts with the National Cancer Institute enhance the prospects of Actinium Pharmaceuticals Inc. ATNM's Actimab-A in treating acute myeloid leukemia and its potential as a backbone therapy?
**MWN-AI FAQ is based on asking OpenAI questions about Actinium Pharmaceuticals Inc. (NYSE: ATNM).
NASDAQ: ATNM
ATNM Trading
0.26% G/L:
$1.2127 Last:
16,656 Volume:
$1.21 Open:
